Footnotes
This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.
Conflict of interest: Janwillem Kocks, Marjan Kerkhof, Aimée van de Maat, Iris van Geer-Postmus and Thomas le Rütte were employed by General Practitioners Research Institute (GPRI) at the time of the study. In the past three years (2019–2022), GPRI conducted investigator- and sponsor-initiated research funded by non-commercial organizations, academic institutes, and pharmaceutical companies (including AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Mundipharma, Novartis, and Teva).
Conflict of interest: Huib Kerstjens reports no conflicts of interest for this study. Unrelatede to this study, his institution has received funding for his studies and payments for his consultancies from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, and Novartis.
Conflict of interest: Reinold Gans, Jan Scherpenisse and Jan Schaart report no conflicts of interest for this study.
This is a PDF-only article. Please click on the PDF link above to read it.
- Copyright ©The authors 2022
This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org